Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

QuantitativeCancerProteomicAtlas1.2 observable peptides

ABSTRACT: This dataset contain evidences of observability of QCPA (v1.2) peptides, in whole cell tryptic proteome background.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Acute Leukemia

SUBMITTER: Paolo Cifani

LAB HEAD: Paolo Cifani

PROVIDER: PXD034653 | Pride | 2022-10-12

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Quantitative Cell Proteomic Atlas: Pathway-Scale Targeted Mass Spectrometry for High-Resolution Functional Profiling of Cell Signaling.

Cifani Paolo P Kentsis Alex A

Journal of proteome research 20220926 10

In spite of extensive studies of cellular signaling, many fundamental processes such as pathway integration, cross-talk, and feedback remain poorly understood. To enable integrated and quantitative measurements of cellular biochemical activities, we have developed the Quantitative Cell Proteomics Atlas (QCPA). QCPA consists of panels of targeted mass spectrometry assays to determine the abundance and stoichiometry of regulatory post-translational modifications of sentinel proteins from most know ...[more]

PMID: 36154077

Similar Datasets

Genome-wide CRISPR-Cas9 screen identifies functionally relevant microRNAs in AML

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-07-01 | E-GEOD-71544 | biostudies-arrayexpress

Next generation sequencing identifies small RNA expression in FLT3-ITD+ AML (MV4-11) cell lines

Project description:The expression level of microRNAs in FLT3-ITD+ AML is unknown. Using empty vector (EV) lentiviral CRISPR-Cas9 infected FLT3-ITD+ AML cell lines (MV4-11 cells), we performed next generation RNA sequencing on small RNAs to determine microRNA expression level in these cells. We found a variety of evolutionarily conserved and non-conserved microRNAs expressed in our cells of interest. Small RNAseq on EV lentiviral CRISPR-Cas9 infected MV4-11 cell lines was performed on triplicate cultures.

2016-07-01 | E-GEOD-71543 | biostudies-arrayexpress

Human AML cell lines LC-MS/MS - Performance of Super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines

Project description:As a direct consequence of the high diversity of the aggressive blood cancer acute myeloid leukemia (AML), proteomic samples from patients are strongly heterogeneous, rendering their accurate relative quantification challenging. In the present study, we investigated the benefits of using a super-SILAC mix of AML derived cell lines as internal standard for quantitative shotgun studies. The Molm-13, NB4, MV4-11, THP-1, and OCI-AML3 cell lines were selected for their complementarity with regard to clinical, cytogenetic and molecular risk factors used for prognostication of AML patients. The resulting internal standard presents a high coverage of the AML proteome compared to single cell lines allied with high technical reproducibility, thus enabling its use for AML patient comparison. This was confirmed by comparing the protein regulation between the five cell lines and applying the internal standard to patient material.

2014-07-15 | PXD000441 | Pride

Expression profile of wild type (WT) vs miR-155-/- in FLT3-ITD+ AML (MV4-11) cell lines

Project description:The expression profile in miR-155-/- FLT3-ITD+ AML is unknown. Using empty vector (EV) or two distinct miR-155 (S3 or S10) lentiviral CRISPR-Cas9 infected FLT3-ITD+ AML cell lines (MV4-11 cells), we performed next generation RNA sequencing to determine the expression profile in these cells dependent on miR-155. We found a number of pathways dysregulated, including STAT5 activation. RNAseq was performed on EV or miR-155 lentiviral CRISPR-Cas9 infected MV4-11 cell lines in triplicate cultures.

2016-07-01 | E-GEOD-71541 | biostudies-arrayexpress

Transcription profiling of human AML cell lines treated with rapamycin treatment - evidence for Skp2 and p27 mediated G1 arrest

Project description:Acute Myelod Leukaemia cells were treated with specific dosages of the drug rapamycin and RNA was extracted. The RNA was then hybridised onto Affymetric HG U133A chips.

2009-12-25 | E-MEXP-2170 | biostudies-arrayexpress

Global ChIP-seq Normalization Reveals Epigenome Modulations

Project description:Epigenomic profiling by ChIP-seq is a prevailing methodology used to investigate chromatin-based regulation in biological systems, such as human disease, yet the lack of an empirical methodology to normalize amongst experiments has limited the usefulness of this technique. Here we describe a “spike-in” normalization method that allows the quantitative comparison of histone modification status across cell populations using defined quantities of a reference epigenome. We demonstrate the utility of this method in measuring epigenomic changes following chemical perturbations and show how control normalization of ChIP-seq experiments enables discovery of disease-relevant changes in histone modification occupancy. ChIP-Seq of histone modifications H3K79me2 and H3K4me3 in human samples treated with EPZ-5676 with/without reference epigenome spike-in.

2014-10-30 | E-GEOD-60104 | biostudies-arrayexpress

CSF chitinase 3-like 2 is associated with disability progression in patients with progressive multiple sclerosis

Project description:Background: We aimed to identify long-term prognostic protein biomarkers associated with disease progression in patients with progressive multiple sclerosis (MS). Methods: Cerebrospinal fluid (CSF) samples were obtained from a discovery cohort of 28 patients with progressive MS who participated in a placebo-controlled clinical trial with interferon-beta. Patients were classified into high and low disability progression phenotypes according to numeric and step-based progression rates. Protein abundance was measured by shotgun proteomics using liquid chromatographic and mass spectrometric analysis. Selected proteins from the discovery cohort were quantified by parallel reaction monitoring in CSF samples from an independent validation cohort of 41 patients with progressive MS classified also into high and low disability progression phenotypes. Results: Out of 1582548 CSF proteins identified in the discovery cohort, ten proteins were selected for validation based on the number of significant differences observed in the progression rates between patients with high and low disability progression: SPATS2-like protein (SPATS2L), Chitinase 3-like 2 (CHI3L2), plasma serine protease inhibitor (SERPINA5), Metallothionein-3 (MT3), Phospholipase D4 (PLD4), Beta-hexosaminidase (HEXB), Neurexophilin-1 (NXPH1), Adipocyte enhancer-binding protein 1 (AEBP1), Cathepsin L1 (CTSL), and Lipopolysaccharide-binding protein (LBP). Only CHI3L2 was validated, exhibiting significantly higher CSF protein levels and CSF protein levels were significantly higher in patients with high disability progression compared to patients with low disability progression. CSF CHI3L2 levels showed good performance to discriminate between progressive MS patients with high and low disability progression. Conclusions: Although further confirmatory studies are needed, we propose CSF CHI3L2 as a prognostic protein biomarker associated with disability progression in progressive MS patients.

2021-11-03 | PXD022958 | Pride

Gene expression changes in MV4-11 cells upon SMARCA4 knock-down and PFI-3 treatment

Project description:Pharmacological inhibition of the SMARCA4 bromodomain inhibited human leukemic cell proliferation, phenocopying SMARCA4 knockdown in these cells. We performed microarray analysis of global gene expression changes in MV4-11 cells after 6 days of PFI-3 treatment and after SMARCA4 knock-down. With this analysis we identified several genes whose expression was similarly up- or down-regulated upon inhibitor treatment and SMARCA4 depletion. Human acute monocytic leukemia cells (MV4-11, ACC 102) were lentivirally transduced with shRNA taregting SMARCA4 (KD) or with a negative control shRNA (Scr). In a parallel experiment MV4-11 cells were treated for 6 days with 10 uM PFI-3, which is SMARCA4, SMARCA2 and PBRM1 bromodomain inhibitor, or DMSO as a negative control. All sample types were prepared in triplicates.

2015-07-12 | E-GEOD-67920 | biostudies-arrayexpress

Comparation the mRNA Expression Profile of the MV4-11 Sorafenib Resistant Cells and the Parental Cells

Project description:Our gene set analysis of MV4-11-R versus MV4-11 indicated decreased depolarization of mitochondria and mitochondrial membrane, mitochondrial dysfunction and anti-apoptosis as other top ranked molecular or cellular functions of differential gene sets. expression of most genes encoding glycolytic enzymes was up-regulated in MV4-11-R cells we revealed a metabolic alteration in sorafenib-resistant cell lines with mitochondrial respiration deficiency, leading to substantial decrease of mitochondria-derived ATP generation and a significant increase in glycolytic activity to maintain sufficient ATP production. Our study revealed a metabolic signature of sorafenib resistance and indicated that increase of glycolytic activity including upregulation of major glycolytic enzymes may be viewed as a marker for early detection of sorafenib resistance in AML patients with FLT3/ITD mutation and glycolytic inhibitors warrant further investigation as alternative therapeutic agents for sorafenib-resistant cells Sorafenib resistant cells MV411-R VS. parental MV4-11 cells. Biological replicates: 3 control replicates, 3 treated replicates.

2016-08-01 | E-GEOD-74666 | biostudies-arrayexpress

Targeting of SMARCA4 bromodomain selectively inhibits leukemic cell proliferation

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-07-12 | E-GEOD-67924 | biostudies-arrayexpress